Jorge E. Cortes, MD, highlights the significant findings from the ASC4FIRST study, which demonstrated that treatment with asciminib significantly improved major molecular response at 48 weeks compared with standard-of-care TKIs, with a favorable safety profile. In noting the encouraging results, Dr Cortes also emphasized the importance of a longer follow-up.
He also discusses the long-term follow-up data from the OPTIC study, showing that starting ponatinib at 45 mg improved response rates in patients with the T315I mutation and had better safety outcomes after dosage adjustments. Additionally, the BYOND study on bosutinib showed promising response rates.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2024: Key Takeaways on Therapeutic Advancements in CML - Medscape - Jun 10, 2024.
Comments